Cytosorbents targets operating cash flow breakeven in 2H 2026 while planning DrugSorb-ATR de novo submission in late 2026/early 2027 (NASDAQ:CTSO)
CytoSorbents(US:CTSO) Seeking Alpha·2026-05-14 07:31To ensure this doesn't happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...